From the Division of Cardiothoracic Anesthesiology and Critical Care Medicine, Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina.
MedNax National Group, Charlotte, North Carolina.
Anesth Analg. 2018 Jun;126(6):1829-1838. doi: 10.1213/ANE.0000000000002577.
While continuation of β-blockers (BBs) perioperatively has become a national quality improvement measure, the relationship between BB withdrawal and mortality and cardiovascular-related critical quality indicators has not been studied in a contemporary cohort of patients undergoing noncardiac surgery.
For this retrospective study, the quality assurance database of a large community-based anesthesiology group practice was used to identify 410,288 surgical cases, 18 years of age or older, who underwent elective or emergent noncardiac surgical procedures between January 1, 2009, and December 31, 2014. Each surgical case that was withdrawn from BBs perioperatively was propensity matched by clinical and surgical characteristics to 4 cases that continued BBs perioperatively. Subsequently, multivariable conditional logistic regression analyses were performed in the matched cohort to determine the extent to which withdrawal of perioperative BBs was independently associated with mortality as the primary outcome and cardiovascular-related critical quality indicators as the secondary outcome (need for vasopressor, electrocardiographic changes requiring treatment, unplanned admission to intensive care unit, postanesthesia care unit stay >2 hours, and a combination of cardiac arrest and myocardial infarction) within 48 hours postoperatively.
Of the 66,755 (16%) cases in the cohort admitted on BB therapy, BBs were withdrawn in 3829 (6%) and continued in 62,926 (94%). Propensity score matching resulted in an analysis cohort of 19,145 cases. Withdrawal of perioperative BBs in the multivariable conditional logistic regression analysis was significantly associated with an increased risk for mortality (odds ratio [OR], 3.61; 95% confidence interval [CI], 1.75-7.35; P = .0003), but a significantly decreased risk for need of blood pressure support requiring vasopressor initiation (OR, 0.84; 95% CI, 0.76-0.92; P = .0003) and extended postanesthesia care unit stay (OR, 0.69; 95% CI, 0.54-0.88; P = .004) within 48 hours after noncardiac surgery.
Perioperative withdrawal of BBs was associated with increased risk for mortality within 48 hours after noncardiac surgery and with decreased risk for need of vasopressor during the early postoperative period and a shorter stay in the postanesthesia care unit.
尽管继续使用β受体阻滞剂(BBs)围手术期已成为国家质量改进措施,但 BB 停药与死亡率以及心血管相关关键质量指标之间的关系尚未在接受非心脏手术的当代患者队列中进行研究。
在这项回顾性研究中,使用大型社区麻醉学实践的质量保证数据库,确定了 2009 年 1 月 1 日至 2014 年 12 月 31 日期间接受择期或紧急非心脏手术的 410,288 例 18 岁或以上的手术病例。每个围手术期停用 BB 的手术病例都根据临床和手术特征与 4 例继续围手术期使用 BB 的病例进行倾向匹配。随后,在匹配队列中进行多变量条件逻辑回归分析,以确定围手术期停用 BB 与死亡率(主要结局)和心血管相关关键质量指标(作为次要结局,包括需要升压药、需要治疗的心电图变化、计划外入住重症监护病房、麻醉后护理病房停留>2 小时以及心脏骤停和心肌梗死的组合)之间的关系程度术后 48 小时内。
在队列中的 66755(16%)例接受 BB 治疗的病例中,3829 例(6%)停用 BB,62926 例(94%)继续使用 BB。倾向评分匹配后,分析队列中有 19145 例病例。多变量条件逻辑回归分析中,围手术期停用 BB 与死亡率升高显著相关(比值比[OR],3.61;95%置信区间[CI],1.75-7.35;P =.0003),但与需要升压药支持的风险降低显著相关需要启动(OR,0.84;95%CI,0.76-0.92;P =.0003)和延长麻醉后护理病房停留时间(OR,0.69;95%CI,0.54-0.88;P =.004)术后 48 小时内。
非心脏手术后 48 小时内停用 BB 与死亡率升高相关,与术后早期需要升压药的风险降低以及麻醉后护理病房停留时间缩短相关。